VKTX Viking Therapeutics, Inc.
VKTX Viking Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $33.67 · VWAP $33.88 · -25.7% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 1 other sold $6.3M, Jul 29
Coverage
2 watchlists
VKTX Price Structure
Loading timeframes…
Peers
Every watchlist VKTX belongs to, members best 30-day change first — VKTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@peptide-economy
@biotech-capital-cycle
Reported the quarter ending 2026-06-30: revenue $0, diluted EPS -$1.10, net income -$128M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved -2.2% (close before → first close after).
full note →Against street estimates
How VKTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about VKTX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 22 days ago · Sep 25
- Viking Therapeutics (VKTX) Stock Price, Quote & Analysis | TipRanks
- Viking Therapeutics, Inc. Stock Price
- Viking Therapeutics, Inc. (VKTX) Stock Price, Quote, News & Analysis | Seeking Alpha
- Viking Therapeutics - Press Releases
- VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
VKTX research tape
56 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to VKTX.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet